-
1
-
-
36348942916
-
The incidence of primary fallopian tube cancer in the United States
-
Stewart SL, Wike JM, Foster SL, Michaud F. The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol. 2007;107(3):392-397.
-
(2007)
Gynecol Oncol.
, vol.107
, Issue.3
, pp. 392-397
-
-
Stewart, S.L.1
Wike, J.M.2
Foster, S.L.3
Michaud, F.4
-
2
-
-
58349096907
-
Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004
-
Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004. Cancer Epidemiol Biomarkers Prev. 2009;18(1):132-139.
-
(2009)
Cancer Epidemiol Biomarkers Prev.
, vol.18
, Issue.1
, pp. 132-139
-
-
Goodman, M.T.1
Shvetsov, Y.B.2
-
3
-
-
84866651006
-
Cancer of the ovary, fallopian tube, and peritoneum
-
Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2012;119 Suppl 2: S118-S129.
-
(2012)
Int J Gynaecol Obstet.
, vol.119
, Issue.SUPPL. 2
-
-
Berek, J.S.1
Crum, C.2
Friedlander, M.3
-
4
-
-
36048974673
-
Lessons from BRCA: The tubal fimbria emerges as an origin for pelvic serous cancer
-
Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007;5(1):35-44.
-
(2007)
Clin Med Res.
, vol.5
, Issue.1
, pp. 35-44
-
-
Crum, C.P.1
Drapkin, R.2
Kindelberger, D.3
Medeiros, F.4
Miron, A.5
Lee, Y.6
-
5
-
-
33846185401
-
The distal fallopian tube: A new model for pelvic serous carcinogenesis
-
Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19(1):3-9.
-
(2007)
Curr Opin Obstet Gynecol.
, vol.19
, Issue.1
, pp. 3-9
-
-
Crum, C.P.1
Drapkin, R.2
Miron, A.3
-
6
-
-
0041811945
-
Cell biology of human ovarian surface epithelial cells and ovarian carcinogenesis
-
Katabuchi H, Okamura H. Cell biology of human ovarian surface epithelial cells and ovarian carcinogenesis. Med Electron Microsc. 2003;36(2):74-86.
-
(2003)
Med Electron Microsc.
, vol.36
, Issue.2
, pp. 74-86
-
-
Katabuchi, H.1
Okamura, H.2
-
8
-
-
84884126025
-
Tu-be or not tu-be: That is the question. about serous ovarian carcinogenesis
-
Chene G, Dauplat J, Radosevic-Robin N, Cayre A, Penault-Llorca F. Tu-be or not tu-be: that is the question. about serous ovarian carcinogenesis. Crit Rev Oncol Hematol. 2013;88(1):134-143.
-
(2013)
Crit Rev Oncol Hematol.
, vol.88
, Issue.1
, pp. 134-143
-
-
Chene, G.1
Dauplat, J.2
Radosevic-Robin, N.3
Cayre, A.4
Penault-Llorca, F.5
-
9
-
-
0015230305
-
Incessant ovulation-a factor in ovarian neoplasia?
-
Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet. 1971;2(7716):163.
-
(1971)
Lancet.
, vol.2
, Issue.7716
, pp. 163
-
-
Fathalla, M.F.1
-
10
-
-
0033818160
-
Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds
-
Casey MJ, Bewtra C, Hoehne LL, Tatpati AD, Lynch HT, Watson P. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. Gynecol Oncol. 2000;78(3 Pt 1):278-287.
-
(2000)
Gynecol Oncol.
, vol.78
, Issue.3 PART 1
, pp. 278-287
-
-
Casey, M.J.1
Bewtra, C.2
Hoehne, L.L.3
Tatpati, A.D.4
Lynch, H.T.5
Watson, P.6
-
11
-
-
0034661872
-
Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes
-
Barakat RR, Federici MG, Saigo PE, Robson ME, Offit K, Boyd J. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer. 2000;89(2):383-390.
-
(2000)
Cancer.
, vol.89
, Issue.2
, pp. 383-390
-
-
Barakat, R.R.1
Federici, M.G.2
Saigo, P.E.3
Robson, M.E.4
Offit, K.5
Boyd, J.6
-
12
-
-
84875461548
-
The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin
-
Kessler M, Fotopoulou C, Meyer T. The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin. Int J Mol Sci. 2013;14(4):6571-6596.
-
(2013)
Int J Mol Sci.
, vol.14
, Issue.4
, pp. 6571-6596
-
-
Kessler, M.1
Fotopoulou, C.2
Meyer, T.3
-
13
-
-
34548525798
-
Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction
-
Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25(25):3985-3990.
-
(2007)
J Clin Oncol.
, vol.25
, Issue.25
, pp. 3985-3990
-
-
Callahan, M.J.1
Crum, C.P.2
Medeiros, F.3
-
14
-
-
33846624310
-
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship
-
Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161-169.
-
(2007)
Am J Surg Pathol.
, vol.31
, Issue.2
, pp. 161-169
-
-
Kindelberger, D.W.1
Lee, Y.2
Miron, A.3
-
15
-
-
42949138321
-
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations
-
Folkins AK, Jarboe EA, Saleemuddin A, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol. 2008;109(2):168-173.
-
(2008)
Gynecol Oncol.
, vol.109
, Issue.2
, pp. 168-173
-
-
Folkins, A.K.1
Jarboe, E.A.2
Saleemuddin, A.3
-
16
-
-
47749130054
-
Tubal and ovarian pathways to pelvic epithelial cancer: A pathological perspective
-
Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology. 2008;53(2):127-138.
-
(2008)
Histopathology.
, vol.53
, Issue.2
, pp. 127-138
-
-
Jarboe, E.A.1
Folkins, A.K.2
Drapkin, R.3
Ince, T.A.4
Agoston, E.S.5
Crum, C.P.6
-
17
-
-
63549123345
-
Intercepting pelvic cancer in the distal fallopian tube: Theories and realities
-
Crum CP. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol. 2009;3(2):165-170.
-
(2009)
Mol Oncol.
, vol.3
, Issue.2
, pp. 165-170
-
-
Crum, C.P.1
-
18
-
-
67349190538
-
Precursors to pelvic serous carcinoma and their clinical implications
-
Folkins AK, Jarboe EA, Roh MH, Crum CP. Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol. 2009;113(3):391-396.
-
(2009)
Gynecol Oncol.
, vol.113
, Issue.3
, pp. 391-396
-
-
Folkins, A.K.1
Jarboe, E.A.2
Roh, M.H.3
Crum, C.P.4
-
19
-
-
77955490398
-
Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube
-
Chen EY, Mehra K, Mehrad M, et al. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol. 2010;222(1):110-116.
-
(2010)
J Pathol.
, vol.222
, Issue.1
, pp. 110-116
-
-
Chen, E.Y.1
Mehra, K.2
Mehrad, M.3
-
20
-
-
79959328816
-
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm
-
Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011;42(7):918-931.
-
(2011)
Hum Pathol.
, vol.42
, Issue.7
, pp. 918-931
-
-
Kurman, R.J.1
Shih, I.M.2
-
21
-
-
79957529938
-
Radical fimbriectomy: A reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development
-
Leblanc E, Narducci F, Farre I, et al. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development. Gynecol Oncol. 2011;121(3):472-476.
-
(2011)
Gynecol Oncol.
, vol.121
, Issue.3
, pp. 472-476
-
-
Leblanc, E.1
Narducci, F.2
Farre, I.3
-
22
-
-
80051796593
-
p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary
-
Leonhardt K, Einenkel J, Sohr S, Engeland K, Horn LC. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Int J Gynecol Pathol. 2011;30(5):417-424.
-
(2011)
Int J Gynecol Pathol.
, vol.30
, Issue.5
, pp. 417-424
-
-
Leonhardt, K.1
Einenkel, J.2
Sohr, S.3
Engeland, K.4
Horn, L.C.5
-
23
-
-
84857551527
-
The oviduct and ovarian cancer: Causality, clinical implications, and 'targeted prevention'
-
Crum CP, McKeon FD, Xian W. The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention". Clin Obstet Gynecol. 2012;55(1):24-35.
-
(2012)
Clin Obstet Gynecol.
, vol.55
, Issue.1
, pp. 24-35
-
-
Crum, C.P.1
McKeon, F.D.2
Xian, W.3
-
24
-
-
84865684159
-
Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls
-
Mingels MJ, Roelofsen T, van der Laak JA, et al. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. Gynecol Oncol. 2012;127(1):88-93.
-
(2012)
Gynecol Oncol.
, vol.127
, Issue.1
, pp. 88-93
-
-
Mingels, M.J.1
Roelofsen, T.2
van der Laak, J.A.3
-
25
-
-
84880333458
-
Clinicopathologic study of serous tubal intraepithelial carcinoma with invasive carcinoma: Is serous tubal intraepithelial carcinoma a reliable feature for determining the organ of origin?
-
Gao FF, Bhargava R, Yang H, Li Z, Zhao C. Clinicopathologic study of serous tubal intraepithelial carcinoma with invasive carcinoma: is serous tubal intraepithelial carcinoma a reliable feature for determining the organ of origin? Hum Pathol. 2013;44(8):1534-1543.
-
(2013)
Hum Pathol.
, vol.44
, Issue.8
, pp. 1534-1543
-
-
Gao, F.F.1
Bhargava, R.2
Yang, H.3
Li, Z.4
Zhao, C.5
-
26
-
-
84879974177
-
Gene expression analyses support fallopian tube epithelium as the cell of origin of epithelial ovarian cancer
-
O'Shannessy DJ, Jackson SM, Twine NC, et al. Gene expression analyses support fallopian tube epithelium as the cell of origin of epithelial ovarian cancer. Int J Mol Sci. 2013;14(7):13687-13703.
-
(2013)
Int J Mol Sci.
, vol.14
, Issue.7
, pp. 13687-13703
-
-
O'Shannessy, D.J.1
Jackson, S.M.2
Twine, N.C.3
-
27
-
-
84871408680
-
Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens
-
Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer. 2013;49(1):132-141.
-
(2013)
Eur J Cancer.
, vol.49
, Issue.1
, pp. 132-141
-
-
Reitsma, W.1
de Bock, G.H.2
Oosterwijk, J.C.3
Bart, J.4
Hollema, H.5
Mourits, M.J.6
-
28
-
-
62849095422
-
Serous tubal intraepithelial carcinoma and the dominant ovarian mass: Clues to serous tumor origin?
-
Roh MH, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol. 2009;33(3):376-383.
-
(2009)
Am J Surg Pathol.
, vol.33
, Issue.3
, pp. 376-383
-
-
Roh, M.H.1
Kindelberger, D.2
Crum, C.P.3
-
29
-
-
79957811258
-
STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis
-
Mehra K, Mehrad M, Ning G, et al. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed). 2011;3:625-634.
-
(2011)
Front Biosci (Elite Ed).
, vol.3
, pp. 625-634
-
-
Mehra, K.1
Mehrad, M.2
Ning, G.3
-
30
-
-
33846187651
-
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
-
Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211(1):26-35.
-
(2007)
J Pathol.
, vol.211
, Issue.1
, pp. 26-35
-
-
Lee, Y.1
Miron, A.2
Drapkin, R.3
-
31
-
-
77952515048
-
Precursor lesions of high-grade serous ovarian carcinoma: Morphological and molecular characteristics
-
Gross AL, Kurman RJ, Vang R, Shih IeM, Visvanathan K. Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. J Oncol. 2010;2010:126295.
-
(2010)
J Oncol.
, vol.2010
, pp. 126295
-
-
Gross, A.L.1
Kurman, R.J.2
Vang, R.3
Shih, I.M.4
Visvanathan, K.5
-
32
-
-
84875904387
-
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer
-
PRACTICAL Consortium; Australian Ovarian Cancer Study Group; Australian Cancer Study
-
Shen H, Fridley BL, Song H, et al; PRACTICAL Consortium; Australian Ovarian Cancer Study Group; Australian Cancer Study. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun. 2013;4:1628.
-
(2013)
Nat Commun.
, vol.4
, pp. 1628
-
-
Shen, H.1
Fridley, B.L.2
Song, H.3
-
33
-
-
0028973081
-
p53 protein expression in putative precursor lesions of epithelial ovarian cancer
-
Hutson R, Ramsdale J, Wells M. p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology. 1995;27(4):367-371.
-
(1995)
Histopathology.
, vol.27
, Issue.4
, pp. 367-371
-
-
Hutson, R.1
Ramsdale, J.2
Wells, M.3
-
34
-
-
24344434551
-
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon
-
Marquez RT, Baggerly KA, Patterson AP, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005;11(17):6116-6126.
-
(2005)
Clin Cancer Res.
, vol.11
, Issue.17
, pp. 6116-6126
-
-
Marquez, R.T.1
Baggerly, K.A.2
Patterson, A.P.3
-
35
-
-
77957946398
-
ARID1A mutations in endometriosis-associated ovarian carcinomas
-
Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532-1543.
-
(2010)
N Engl J Med.
, vol.363
, Issue.16
, pp. 1532-1543
-
-
Wiegand, K.C.1
Shah, S.P.2
Al-Agha, O.M.3
-
36
-
-
84858256340
-
Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers
-
Lowery WJ, Schildkraut JM, Akushevich L, et al. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer. 2012;22(1):9-14.
-
(2012)
Int J Gynecol Cancer.
, vol.22
, Issue.1
, pp. 9-14
-
-
Lowery, W.J.1
Schildkraut, J.M.2
Akushevich, L.3
-
37
-
-
84867269276
-
Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma
-
Ayhan A, Mao TL, Seckin T, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer. 2012;22(8):1310-1315.
-
(2012)
Int J Gynecol Cancer.
, vol.22
, Issue.8
, pp. 1310-1315
-
-
Ayhan, A.1
Mao, T.L.2
Seckin, T.3
-
38
-
-
0036928961
-
Pathologic findings in prophylactic oophorectomy specimens in high-risk women
-
Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002;87(1):52-56.
-
(2002)
Gynecol Oncol.
, vol.87
, Issue.1
, pp. 52-56
-
-
Leeper, K.1
Garcia, R.2
Swisher, E.3
Goff, B.4
Greer, B.5
Paley, P.6
-
39
-
-
33644936023
-
Advances in the recognition of tubal intraepithelial carcinoma: Applications to cancer screening and the pathogenesis of ovarian cancer
-
Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, Crum CP. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol. 2006;13(1):1-7.
-
(2006)
Adv Anat Pathol.
, vol.13
, Issue.1
, pp. 1-7
-
-
Lee, Y.1
Medeiros, F.2
Kindelberger, D.3
Callahan, M.J.4
Muto, M.G.5
Crum, C.P.6
-
40
-
-
16644400609
-
Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: Role of serial sectioning in the detection of occult malignancy
-
Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23(1): 127-132.
-
(2005)
J Clin Oncol.
, vol.23
, Issue.1
, pp. 127-132
-
-
Powell, C.B.1
Kenley, E.2
Chen, L.M.3
-
41
-
-
29144527583
-
Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers
-
Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100(1): 58-64.
-
(2006)
Gynecol Oncol.
, vol.100
, Issue.1
, pp. 58-64
-
-
Finch, A.1
Shaw, P.2
Rosen, B.3
Murphy, J.4
Narod, S.A.5
Colgan, T.J.6
-
42
-
-
79951580829
-
"Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: Assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer
-
Seidman JD, Zhao P, Yemelyanova A. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol. 2011;120(3):470-473.
-
(2011)
Gynecol Oncol.
, vol.120
, Issue.3
, pp. 470-473
-
-
Seidman, J.D.1
Zhao, P.2
Yemelyanova, A.3
-
43
-
-
79955791258
-
Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: Building a model for early BRCA-associated tumorigenesis
-
Yates MS, Meyer LA, Deavers MT, et al. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis. Cancer Prev Res (Phila). 2011;4(3):463-470.
-
(2011)
Cancer Prev Res (Phila).
, vol.4
, Issue.3
, pp. 463-470
-
-
Yates, M.S.1
Meyer, L.A.2
Deavers, M.T.3
-
44
-
-
84871415258
-
Ovarian cancer, version 3.2012
-
National Comprehensive Cancer Network
-
Morgan RJ, Alvarez RD, Armstrong DK, et al; National Comprehensive Cancer Network. Ovarian cancer, version 3.2012. J Natl Compr Canc Netw. 2012;10(11):1339-1349.
-
(2012)
J Natl Compr Canc Netw.
, vol.10
, Issue.11
, pp. 1339-1349
-
-
Morgan, R.J.1
Alvarez, R.D.2
Armstrong, D.K.3
-
45
-
-
0141688377
-
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
-
Gynecologic Oncology Group
-
Ozols RF, Bundy BN, Greer BE, et al; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194-3200.
-
(2003)
J Clin Oncol.
, vol.21
, Issue.17
, pp. 3194-3200
-
-
Ozols, R.F.1
Bundy, B.N.2
Greer, B.E.3
-
46
-
-
30044438368
-
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
-
Gynecologic Oncology Group
-
Armstrong DK, Bundy B, Wenzel L, et al; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.
-
(2006)
N Engl J Med.
, vol.354
, Issue.1
, pp. 34-43
-
-
Armstrong, D.K.1
Bundy, B.2
Wenzel, L.3
-
47
-
-
75749110481
-
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial
-
Markman M, Moon J, Wilczynski S, et al. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol. 2010;116(3):323-325.
-
(2010)
Gynecol Oncol.
, vol.116
, Issue.3
, pp. 323-325
-
-
Markman, M.1
Moon, J.2
Wilczynski, S.3
-
48
-
-
84855425106
-
Incorporation of bevacizumab in the primary treatment of ovarian cancer
-
Gynecologic Oncology Group
-
Burger RA, Brady MF, Bookman MA, et al; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473-2483.
-
(2011)
N Engl J Med.
, vol.365
, Issue.26
, pp. 2473-2483
-
-
Burger, R.A.1
Brady, M.F.2
Bookman, M.A.3
-
49
-
-
84855466019
-
A phase 3 trial of bevacizumab in ovarian cancer
-
ICON7 Investigators
-
Perren TJ, Swart AM, Pfisterer J, et al; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484-2496.
-
(2011)
N Engl J Med.
, vol.365
, Issue.26
, pp. 2484-2496
-
-
Perren, T.J.1
Swart, A.M.2
Pfisterer, J.3
-
50
-
-
84861736119
-
OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
-
Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-2045.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.17
, pp. 2039-2045
-
-
Aghajanian, C.1
Blank, S.V.2
Goff, B.A.3
-
51
-
-
0346423733
-
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
-
Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335(26):1950-1955.
-
(1996)
N Engl J Med.
, vol.335
, Issue.26
, pp. 1950-1955
-
-
Alberts, D.S.1
Liu, P.Y.2
Hannigan, E.V.3
-
52
-
-
4644225190
-
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
-
Doxil Study 30-49 Investigators
-
Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95(1):1-8.
-
(2004)
Gynecol Oncol.
, vol.95
, Issue.1
, pp. 1-8
-
-
Gordon, A.N.1
Tonda, M.2
Sun, S.3
Rackoff, W.4
-
53
-
-
0034600305
-
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
-
Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92(9):699-708.
-
(2000)
J Natl Cancer Inst.
, vol.92
, Issue.9
, pp. 699-708
-
-
Piccart, M.J.1
Bertelsen, K.2
James, K.3
-
54
-
-
84865676963
-
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
-
Schilder RJ, Brady WE, Lankes HA, et al. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;127(1):70-74.
-
(2012)
Gynecol Oncol.
, vol.127
, Issue.1
, pp. 70-74
-
-
Schilder, R.J.1
Brady, W.E.2
Lankes, H.A.3
-
55
-
-
84857596702
-
Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer
-
Seamon LG, Richardson DL, Copeland LJ. Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer. Clin Obstet Gynecol. 2012;55(1):131-155.
-
(2012)
Clin Obstet Gynecol.
, vol.55
, Issue.1
, pp. 131-155
-
-
Seamon, L.G.1
Richardson, D.L.2
Copeland, L.J.3
-
56
-
-
1242339607
-
Optimal therapy of advanced ovarian cancer: Carboplatin and paclitaxel vs cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5
-
Bookman MA, Greer BE, Ozols RF. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. Int J Gynecol Cancer. 2003;13(6):735-740.
-
(2003)
Int J Gynecol Cancer.
, vol.13
, Issue.6
, pp. 735-740
-
-
Bookman, M.A.1
Greer, B.E.2
Ozols, R.F.3
-
57
-
-
70349878651
-
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial
-
Japanese Oncology Group
-
Katsumata N, Yasuda M, Takahashi F, et al; Japanese Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331-1338.
-
(2009)
Lancet.
, vol.374
, Issue.9698
, pp. 1331-1338
-
-
Katsumata, N.1
Yasuda, M.2
Takahashi, F.3
-
58
-
-
84882998935
-
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial
-
Japanese Gynecologic Oncology Group
-
Katsumata N, Yasuda M, Isonishi S, et al; Japanese Gynecologic Oncology Group. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020-1026.
-
(2013)
Lancet Oncol.
, vol.14
, Issue.10
, pp. 1020-1026
-
-
Katsumata, N.1
Yasuda, M.2
Isonishi, S.3
-
59
-
-
9744223515
-
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma
-
Scottish Gynaecological Cancer Trials Group
-
Vasey PA, Jayson GC, Gordon A, et al; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96(22):1682-1691.
-
(2004)
J Natl Cancer Inst.
, vol.96
, Issue.22
, pp. 1682-1691
-
-
Vasey, P.A.1
Jayson, G.C.2
Gordon, A.3
-
60
-
-
0026086870
-
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
-
Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9(3):389-393.
-
(1991)
J Clin Oncol.
, vol.9
, Issue.3
, pp. 389-393
-
-
Markman, M.1
Rothman, R.2
Hakes, T.3
-
61
-
-
0031897980
-
Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma
-
Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol. 1998;16(4):1494-1497.
-
(1998)
J Clin Oncol.
, vol.16
, Issue.4
, pp. 1494-1497
-
-
Rose, P.G.1
Fusco, N.2
Fluellen, L.3
Rodriguez, M.4
-
62
-
-
0037862963
-
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial
-
ICON and AGO Collaborators
-
Parmar MK, Ledermann JA, Colombo N, et al; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361(9375):2099-2106.
-
(2003)
Lancet.
, vol.361
, Issue.9375
, pp. 2099-2106
-
-
Parmar, M.K.1
Ledermann, J.A.2
Colombo, N.3
-
63
-
-
33750588670
-
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
-
AGO-OVAR; NCIC CTG; EORTC GCG
-
Pfisterer J, Plante M, Vergote I, et al; AGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699-4707.
-
(2006)
J Clin Oncol.
, vol.24
, Issue.29
, pp. 4699-4707
-
-
Pfisterer, J.1
Plante, M.2
Vergote, I.3
-
64
-
-
84864879755
-
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
-
Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107(4):588-591.
-
(2012)
Br J Cancer.
, vol.107
, Issue.4
, pp. 588-591
-
-
Wagner, U.1
Marth, C.2
Largillier, R.3
-
65
-
-
84860470644
-
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial
-
Gladieff L, Ferrero A, De Rauglaudre G, et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Ann Oncol. 2012;23(5):1185-1189.
-
(2012)
Ann Oncol.
, vol.23
, Issue.5
, pp. 1185-1189
-
-
Gladieff, L.1
Ferrero, A.2
De Rauglaudre, G.3
-
66
-
-
84856331988
-
Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: The CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)
-
GINECO group France
-
Lortholary A, Largillier R, Weber B, et al; GINECO group France. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Ann Oncol. 2012;23(2):346-352.
-
(2012)
Ann Oncol.
, vol.23
, Issue.2
, pp. 346-352
-
-
Lortholary, A.1
Largillier, R.2
Weber, B.3
-
67
-
-
68149161635
-
Epithelial ovarian cancer: Role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment
-
Tanguay JS, Ansari J, Buckley L, Fernando I. Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment. Int J Gynecol Cancer. 2009;19(3):361-366.
-
(2009)
Int J Gynecol Cancer.
, vol.19
, Issue.3
, pp. 361-366
-
-
Tanguay, J.S.1
Ansari, J.2
Buckley, L.3
Fernando, I.4
-
68
-
-
79951502577
-
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube
-
Griffiths RW, Zee YK, Evans S, et al. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. Int J Gynecol Cancer. 2011;21(1):58-65.
-
(2011)
Int J Gynecol Cancer.
, vol.21
, Issue.1
, pp. 58-65
-
-
Griffiths, R.W.1
Zee, Y.K.2
Evans, S.3
-
69
-
-
84866493383
-
AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)
-
AURELIA Investigators. Abstract
-
Pujade-Lauraine, Hilpert F, Weber B, et al; AURELIA Investigators. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol. 2012;30(Suppl 18):LBA5002. Abstract.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.SUPPL. 18
-
-
Pujade-Lauraine, H.F.1
Weber, B.2
-
70
-
-
36849056497
-
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
-
Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33):5180-5186.
-
(2007)
J Clin Oncol.
, vol.25
, Issue.33
, pp. 5180-5186
-
-
Cannistra, S.A.1
Matulonis, U.A.2
Penson, R.T.3
-
71
-
-
36849019301
-
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study
-
Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-5171.
-
(2007)
J Clin Oncol.
, vol.25
, Issue.33
, pp. 5165-5171
-
-
Burger, R.A.1
Sill, M.W.2
Monk, B.J.3
Greer, B.E.4
Sorosky, J.I.5
-
72
-
-
84856509199
-
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: A phase 2, randomised, double-blind, placebo-controlled study
-
Gotlieb WH, Amant F, Advani S, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012;13(2):154-162.
-
(2012)
Lancet Oncol.
, vol.13
, Issue.2
, pp. 154-162
-
-
Gotlieb, W.H.1
Amant, F.2
Advani, S.3
-
73
-
-
79251564088
-
A review of PARP inhibitors: From bench to bedside
-
Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol. 2011;22(2):268-279.
-
(2011)
Ann Oncol.
, vol.22
, Issue.2
, pp. 268-279
-
-
Underhill, C.1
Toulmonde, M.2
Bonnefoi, H.3
-
74
-
-
33748065304
-
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
-
McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109-8115.
-
(2006)
Cancer Res.
, vol.66
, Issue.16
, pp. 8109-8115
-
-
McCabe, N.1
Turner, N.C.2
Lord, C.J.3
-
75
-
-
17244375049
-
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
-
Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913-917.
-
(2005)
Nature.
, vol.434
, Issue.7035
, pp. 913-917
-
-
Bryant, H.E.1
Schultz, N.2
Thomas, H.D.3
-
76
-
-
77954032829
-
Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
-
Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512-2519.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.15
, pp. 2512-2519
-
-
Fong, P.C.1
Yap, T.A.2
Boss, D.S.3
-
77
-
-
77955039099
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial
-
Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245-251.
-
(2010)
Lancet.
, vol.376
, Issue.9737
, pp. 245-251
-
-
Audeh, M.W.1
Carmichael, J.2
Penson, R.T.3
-
78
-
-
84863010984
-
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
-
Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372-379.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.4
, pp. 372-379
-
-
Kaye, S.B.1
Lubinski, J.2
Matulonis, U.3
-
79
-
-
80052389761
-
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study
-
Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852-861.
-
(2011)
Lancet Oncol.
, vol.12
, Issue.9
, pp. 852-861
-
-
Gelmon, K.A.1
Tischkowitz, M.2
McKay, H.3
-
80
-
-
84859523588
-
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
-
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382-1392.
-
(2012)
N Engl J Med.
, vol.366
, Issue.15
, pp. 1382-1392
-
-
Ledermann, J.1
Harter, P.2
Gourley, C.3
-
81
-
-
84883054717
-
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
-
Liu JF, Tolaney SM, Birrer M, et al. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013;49(14):2972-2978.
-
(2013)
Eur J Cancer.
, vol.49
, Issue.14
, pp. 2972-2978
-
-
Liu, J.F.1
Tolaney, S.M.2
Birrer, M.3
-
82
-
-
84883176107
-
Early detection of ovarian and fallopian tube cancer by examination of cytological samples from the endometrial cavity
-
Otsuka I, Kameda S, Hoshi K. Early detection of ovarian and fallopian tube cancer by examination of cytological samples from the endometrial cavity. Br J Cancer. 2013;109(3):603-609.
-
(2013)
Br J Cancer.
, vol.109
, Issue.3
, pp. 603-609
-
-
Otsuka, I.1
Kameda, S.2
Hoshi, K.3
-
83
-
-
33646562149
-
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study
-
Gynecologic Oncology Group
-
Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Waggoner S; Gynecologic Oncology Group. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101(3):436-440.
-
(2006)
Gynecol Oncol.
, vol.101
, Issue.3
, pp. 436-440
-
-
Markman, M.1
Blessing, J.2
Rubin, S.C.3
Connor, J.4
Hanjani, P.5
Waggoner, S.6
-
84
-
-
39749113438
-
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer
-
Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26(6):890-896.
-
(2008)
J Clin Oncol.
, vol.26
, Issue.6
, pp. 890-896
-
-
Ferrandina, G.1
Ludovisi, M.2
Lorusso, D.3
-
85
-
-
34447570846
-
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
-
Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25(19):2811-2818.
-
(2007)
J Clin Oncol.
, vol.25
, Issue.19
, pp. 2811-2818
-
-
Mutch, D.G.1
Orlando, M.2
Goss, T.3
-
86
-
-
66849114911
-
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the Gynecologic Oncology Group
-
Miller DS, Blessing JA, Krasner CN, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009;27(16):2686-2691.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.16
, pp. 2686-2691
-
-
Miller, D.S.1
Blessing, J.A.2
Krasner, C.N.3
-
87
-
-
79957759352
-
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group study
-
Coleman RL, Brady WE, McMeekin DS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122(1):111-115.
-
(2011)
Gynecol Oncol.
, vol.122
, Issue.1
, pp. 111-115
-
-
Coleman, R.L.1
Brady, W.E.2
McMeekin, D.S.3
-
88
-
-
0037331627
-
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: A Gynecologic Oncology Group study
-
Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88(2):130-135.
-
(2003)
Gynecol Oncol.
, vol.88
, Issue.2
, pp. 130-135
-
-
Rose, P.G.1
Blessing, J.A.2
Ball, H.G.3
-
89
-
-
9944231080
-
Phase II trial of vinorelbine for relapsed ovarian cancer: A Southwest Oncology Group study
-
Rothenberg ML, Liu PY, Wilczynski S, et al. Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol. 2004;95(3):506-512.
-
(2004)
Gynecol Oncol.
, vol.95
, Issue.3
, pp. 506-512
-
-
Rothenberg, M.L.1
Liu, P.Y.2
Wilczynski, S.3
-
90
-
-
0026599140
-
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease
-
Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 1992;10(2):243-248.
-
(1992)
J Clin Oncol.
, vol.10
, Issue.2
, pp. 243-248
-
-
Markman, M.1
Hakes, T.2
Reichman, B.3
-
91
-
-
2042487233
-
Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group
-
Alberts DS, Jiang C, Liu PY, Wilczynski S, Markman M, Rothenberg ML. Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. Int J Gynecol Cancer. 2004;14(2):224-228.
-
(2004)
Int J Gynecol Cancer.
, vol.14
, Issue.2
, pp. 224-228
-
-
Alberts, D.S.1
Jiang, C.2
Liu, P.Y.3
Wilczynski, S.4
Markman, M.5
Rothenberg, M.L.6
-
92
-
-
73949123481
-
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
-
Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27(33):5601-5606.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.33
, pp. 5601-5606
-
-
Matulonis, U.A.1
Berlin, S.2
Ivy, P.3
-
93
-
-
77956649079
-
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
-
Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010;119(1):32-37.
-
(2010)
Gynecol Oncol.
, vol.119
, Issue.1
, pp. 32-37
-
-
Friedlander, M.1
Hancock, K.C.2
Rischin, D.3
-
94
-
-
80052588957
-
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
-
Behbakht K, Sill MW, Darcy KM, et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;123(1):19-26.
-
(2011)
Gynecol Oncol.
, vol.123
, Issue.1
, pp. 19-26
-
-
Behbakht, K.1
Sill, M.W.2
Darcy, K.M.3
-
95
-
-
84865681647
-
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or-refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
-
Matulonis UA, Sharma S, Ghamande S, et al. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or-refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol. 2012;127(1):63-69.
-
(2012)
Gynecol Oncol.
, vol.127
, Issue.1
, pp. 63-69
-
-
Matulonis, U.A.1
Sharma, S.2
Ghamande, S.3
-
96
-
-
84869109927
-
Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or-resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer
-
Colombo N, Kutarska E, Dimopoulos M, et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or-resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol. 2012;30(31):3841-3847.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.31
, pp. 3841-3847
-
-
Colombo, N.1
Kutarska, E.2
Dimopoulos, M.3
-
97
-
-
84872869916
-
A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma
-
Campos SM, Penson RT, Matulonis U, et al. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013;128(2):215-220.
-
(2013)
Gynecol Oncol.
, vol.128
, Issue.2
, pp. 215-220
-
-
Campos, S.M.1
Penson, R.T.2
Matulonis, U.3
|